Ipamorelin vs GHRP-2: Growth Hormone Secretagogues Compared

Introduction#

GHRP-2 (Pralmorelin) and Ipamorelin are both synthetic growth hormone secretagogues (GHS) that stimulate pituitary GH release through the ghrelin receptor (GHS-R1a), yet they represent fundamentally different points on the selectivity-potency spectrum. GHRP-2 is among the most potent GHRPs, producing robust GH release with moderate effects on cortisol and prolactin. Ipamorelin is the most selective, delivering a clean GH pulse with minimal off-target hormonal effects.

This trade-off between potency and selectivity defines the choice between these peptides. Understanding their pharmacological differences is essential for researchers designing growth hormone stimulation protocols and for clinicians evaluating secretagogue options.

Quick Comparison Table#

Mechanism of Action Comparison#

GHRP-2#

GHRP-2 (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) is a second-generation GHRP incorporating three unnatural amino acids that enhance GHS-R1a binding affinity and metabolic stability. It activates the ghrelin receptor on pituitary somatotrophs, triggering GH release through phospholipase C/IP3/calcium signaling and suppression of somatostatin tone.

GHRP-2 also activates ghrelin-mediated appetite circuits in the hypothalamus, producing orexigenic effects that distinguish it from ipamorelin. At higher doses, it stimulates modest cortisol and prolactin release, likely through ACTH stimulation and dopamine pathway modulation, respectively. Among the GHRP family, GHRP-2 is considered to have the most favorable selectivity relative to its potency, producing less cortisol and prolactin than hexarelin while maintaining strong GH release.

Its synergy with GHRH is well-documented: combining GHRP-2 with GHRH analogs produces GH release greater than the sum of either agent alone, as GHRPs amplify the somatotroph response to GHRH stimulation.

Ipamorelin#

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide that represents the most selective GHS identified. While it also acts through GHS-R1a, its binding characteristics produce GH release without the cortisol, ACTH, or prolactin elevations seen with other GHRPs.

This selectivity appears to arise from ipamorelin's specific receptor binding mode and its lack of engagement with ACTH-releasing pathways. Clinical studies have confirmed that at GH-effective doses, ipamorelin produces a dose-dependent GH pulse peaking at 30-60 minutes post-administration, with cortisol and prolactin levels remaining at baseline. This clean release profile makes it unique among GHS peptides.

Ipamorelin shows similar GHRH synergy to other GHRPs, making it the preferred partner for combined GHRH/GHRP protocols where hormonal selectivity is prioritized over maximal GH amplitude.

Evidence and Research Comparison#

GHRP-2 Research#

GHRP-2 has a robust clinical evidence base:

• Regulatory approval: Approved in Japan as pralmorelin (GHRP Kaken) for diagnostic evaluation of GH secretory capacity
• Clinical pharmacology: Extensively studied in healthy volunteers and GH-deficient patients for dose-response, selectivity, and GH release kinetics
• Synergy studies: Well-documented synergistic GH release when combined with GHRH, establishing the scientific basis for combined protocols
• Body composition: Studies examining effects on lean mass, fat mass, and metabolic parameters
• Appetite regulation: Ghrelin pathway activation studied in cachexia and appetite disorder contexts

Ipamorelin Research#

Ipamorelin's clinical program has focused on different applications:

• Phase I/II selectivity studies: Human studies confirming dose-dependent GH release without cortisol or prolactin elevation
• Postoperative ileus: Clinical trials investigating accelerated recovery of bowel function after surgery
• Pharmacokinetics: Well-characterized absorption and elimination in human subjects
• Combined protocols: Studies with sermorelin and CJC-1295 demonstrating maintained selectivity in combination settings

Side Effects and Safety Comparison#

GHRP-2 Side Effects#

• Cortisol elevation: Transient and dose-dependent; generally returns to baseline within 1-2 hours
• Prolactin elevation: Mild and transient; less pronounced than with hexarelin
• Appetite stimulation: Increased hunger via ghrelin pathway; may be desirable or undesirable depending on context
• Water retention: Possible at higher doses, consistent with GH-mediated effects
• Injection site reactions: Mild and transient

Ipamorelin Side Effects#

• Minimal hormonal effects: No clinically significant cortisol, ACTH, or prolactin changes at GH-releasing doses
• No appetite stimulation: Unlike GHRP-2 and GHRP-6, does not significantly increase hunger
• Transient headache: Occasionally reported in clinical studies
• Injection site reactions: Mild and transient
• Water retention: Possible with sustained use (GH-mediated)

Dosing and Administration Comparison#

GHRP-2 Dosing#

• Typical research dose: 100-300 mcg per administration, subcutaneous
• Diagnostic dose: 1 mcg/kg IV for GH deficiency testing (Japan protocol)
• Frequency: 2-3 times daily, typically before meals or at bedtime
• Timing: Best administered on an empty stomach; GH release blunted by recent food intake

Ipamorelin Dosing#

• Typical research dose: 200-300 mcg per administration, subcutaneous
• Frequency: 2-3 times daily
• Timing: Empty stomach preferred; often combined with GHRH analog for synergistic effect
• GH pulse: Onset within 15-30 minutes, peak at 30-60 minutes

Can They Be Combined?#

Combining GHRP-2 and ipamorelin would not provide meaningful benefit as both act on the same GHS-R1a receptor, creating competitive binding. The standard approach is to choose one GHRP and pair it with a GHRH analog (sermorelin, CJC-1295) to exploit the synergistic GHRH/GHRP interaction for amplified GH release.

Verdict#

The choice between GHRP-2 and ipamorelin centers on the selectivity-potency trade-off:

Ipamorelin is preferred when clean, selective GH release is the priority -- particularly in anti-aging protocols, body composition research, and combined GHRH/GHRP regimens where minimizing cortisol and prolactin perturbation is important. Its exceptional selectivity profile is unmatched among GHS peptides.

GHRP-2 is preferred when maximum GH release potency is needed, when appetite stimulation is desirable (cachexia, wasting conditions), or for diagnostic applications (where it holds regulatory approval in Japan). It offers the strongest GH release among clinically studied GHRPs while maintaining better selectivity than hexarelin.

For most research applications involving sustained GH optimization protocols, current evidence favors ipamorelin's clean release profile over GHRP-2's greater potency, as the chronic effects of repeated cortisol stimulation may outweigh the marginal GH amplitude advantage.

Explore the full profiles of GHRP-2 and Ipamorelin, or compare with Hexarelin and Sermorelin. Use our Half-Life Comparison Tool for peptide pharmacokinetic comparisons.

Further Reading#

• GHRP-2 Overview and Research Guide
• GHRP-2 Side Effects
• GHRP-2 Dosing Protocols
• Ipamorelin Overview and Research Guide
• Ipamorelin Side Effects
• Ipamorelin Dosing Protocols